Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy

National Medical Journal of China

Volumn 85, Issue 14, 2005, Pages 960-962

  Yang, Xiu Yan ^a   Zhu, Xun ^a   Liang, Liu Qin ^a   Zhan, Zhong Ping ^a   Ye, Yu Jin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cyclophosphamide; Logistic regression mold; Lupus erythematosus, systemic; Ovarian function

Indexed keywords

AZATHIOPRINE; CHINESE DRUG; CYCLOPHOSPHAMIDE; TRIPTERYGIUM WILFORDII EXTRACT;

ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MARRIAGE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREGNANCY; PREMATURE OVARIAN FAILURE; RISK FACTOR; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AMENORRHEA; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OVARIAN FAILURE, PREMATURE; RISK FACTORS;

EID: 17644396656     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Flanc RS, Roberts MA, Strippoli GF, et al. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis, 2004, 43: 197-208.
2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982, 25: 1271-1277.
3. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. a disease activity index for lupus patients. Arthritis Rheum, 1992, 35: 630-640.
4. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythmatosus receiving cyclophosphamide therapy. Arthritis Rheum, 1998, 41: 831-837.
5. Mok CC, Wong RW, Lau CS. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum, 1999, 42: 1274-1280.
6. Yang XY. How to idenrify and control confounding and bias in the clinical research. Chin J Rheumatol, 2000, 4: 114-115.